• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Learn Why The Bull Case For Bristol Myers Squibb Stock Could Change Following Earnings Beat

    Simply Wall St·11/02/2026 02:33:12
    Listen to the news
    • Bristol-Myers Squibb reported Q3 2026 revenue of US$13,069 million and net income of US$2,162 million, alongside encouraging data from late stage oncology and neuroscience programs, including pumitamig in lung cancer and zola cel in multiple sclerosis.
    • The mix of solid recent earnings and early signals from newer therapies in cancer and neurological disease highlights how Bristol-Myers Squibb is trying to shift more of its future cash flow toward its growth portfolio as older drugs face pressure.
    • Next is a look at how Bristol-Myers Squibb's Q3 results and pumitamig lung cancer data might reshape the broader investment narrative.

    See how Bristol-Myers Squibb's pipeline story compares with other potential breakout healthcare plays using our curated list of 34 healthcare AI stocks

    Bristol-Myers Squibb Investment Narrative Recap

    To own Bristol-Myers Squibb, you need to believe management can convert today’s cash engines and late stage pipeline into a stable mix that carries the business through looming patent cliffs. The latest quarter delivered US$13,069 million in revenue and US$2,162 million in net income, which helps underpin that transition story in the near term.

    The key near term catalyst remains execution on the growth portfolio in oncology, hematology and neuroscience as older therapies face pressure. Q3 earnings do not radically change that equation, but they reduce immediate financial stress. The biggest risk still sits in patent expiries and any safety or timing setbacks that slow newer products.

    The pumitamig Phase 2 ROSETTA Lung 107 data looks most relevant for this earnings moment because it sits at the intersection of pipeline progress and potential future cash flow replacement. In metastatic non small cell lung cancer, pumitamig plus docetaxel showed a 36.7% confirmed objective response rate and a 90.0% disease control rate in efficacy evaluable patients.

    For an investor, Bristol-Myers Squibb’s ability to turn that signal into larger trials, regulatory filings and eventually real world uptake is critical. The manageable safety profile, absence of dose limiting toxicities in the dataset and active development across lung cancer settings position pumitamig as a meaningful operational swing factor. It still carries typical clinical, reimbursement and competition risks.

    Bristol-Myers Squibb's current analyst blueprint points to US$39.1b in revenue and US$8.4b in earnings by 2029, with revenue assumed to decline 7.4% each year and earnings expected to decrease by US$0.9b from US$9.3b today.

    Uncover why Bristol-Myers Squibb's fair value indicates a 4% potential upside to its current price before that discount window tightens.

    NYSE:BMY 1-Year Stock Price Chart
    NYSE:BMY 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts lean hard into pumitamig as a swing factor for Bristol-Myers Squibb. Before this news, they were already modeling about US$42.2b in 2029 revenue and US$10.6b in earnings, compared with the consensus US$39.1b and US$8.4b. You can treat today’s updates as a fresh reason to compare those narratives for yourself.

    Explore 4 other Bristol-Myers Squibb fair value estimates, including one that suggests the potential for up to 91% upside from the current price.

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking for more Bristol-Myers Squibb sized ideas?

    If the Bristol-Myers Squibb story has you thinking about position sizing, risk and where future cash flows might come from, it can help to scan a wider field of opportunities using the Simply Wall St Screener.

    • For investors hunting for strong businesses at prices that look appealing, start with a focused set of 33 high quality undervalued stocks that combine quality fundamentals with potentially mispriced expectations.
    • If capital protection matters more to you than chasing every upside swing, narrow your search to a 29 resilient stocks with low risk scores that score well on stability and balance sheet resilience.
    • Readers willing to research earlier stage opportunities can also review a 8 elite penny stocks with strong financials that meet specific financial quality filters rather than just low share prices.